Harbour Investments Inc. Boosts Position in Eli Lilly and Company (NYSE:LLY)

Harbour Investments Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 18.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,436 shares of the company’s stock after buying an additional 1,441 shares during the quarter. Harbour Investments Inc.’s holdings in Eli Lilly and Company were worth $8,360,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Apollon Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 7.0% in the third quarter. Apollon Wealth Management LLC now owns 14,230 shares of the company’s stock valued at $12,607,000 after buying an additional 936 shares in the last quarter. Vestia Personal Wealth Advisors boosted its holdings in Eli Lilly and Company by 1.7% in the 3rd quarter. Vestia Personal Wealth Advisors now owns 767 shares of the company’s stock worth $680,000 after acquiring an additional 13 shares during the period. Everhart Financial Group Inc. grew its position in Eli Lilly and Company by 14.1% in the third quarter. Everhart Financial Group Inc. now owns 5,433 shares of the company’s stock valued at $4,813,000 after acquiring an additional 672 shares in the last quarter. WCM Investment Management LLC grew its position in Eli Lilly and Company by 14.9% in the third quarter. WCM Investment Management LLC now owns 13,260 shares of the company’s stock valued at $11,639,000 after acquiring an additional 1,716 shares in the last quarter. Finally, Opinicus Capital Inc. raised its stake in shares of Eli Lilly and Company by 1.7% during the third quarter. Opinicus Capital Inc. now owns 3,707 shares of the company’s stock valued at $3,284,000 after purchasing an additional 61 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

LLY stock opened at $833.29 on Tuesday. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The stock has a market capitalization of $791.06 billion, a price-to-earnings ratio of 90.09, a PEG ratio of 3.15 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The stock’s fifty day moving average is $896.31 and its two-hundred day moving average is $869.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same period last year, the firm posted $0.10 EPS. The business’s quarterly revenue was up 20.4% on a year-over-year basis. On average, research analysts predict that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.62%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is currently 56.22%.

Analyst Upgrades and Downgrades

LLY has been the subject of several analyst reports. Guggenheim upped their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Deutsche Bank Aktiengesellschaft reduced their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Citigroup lifted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, September 16th. Finally, BMO Capital Markets raised their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Four analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,008.41.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.